Lymphocyte and plasma cell neoplasms associated with autoimmune diseases.

G. Goldenberg,F. Paraskevas,L. Israels

DOI: https://doi.org/10.1016/0049-0172(71)90005-9

1971-08-01

Abstract:

What problem does this paper attempt to address?

A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

Xing Huang,Zhichao Lu,Min He,Yipeng Feng,Shaorong Yu,Bo Shen,Jianwei Lu,Pingping Wu,Banzhou Pan,Hanlin Ding,Chen,Yidan Sun

DOI: https://doi.org/10.1155/2022/2262014

2022-01-01

Oxidative Medicine and Cellular Longevity

Abstract:Lung adenocarcinoma (LUAD) is among the most prevalent malignant lung cancers with a poor prognosis due to high invasiveness and lethality despite multiple treatments. Since the lung is an important organ associated with oxidative stress, and it has been confirmed that oxidative stress represents a potential cancer-specific depletion, it is of important significance to investigate and evaluate the clinical value of oxidative stress mechanisms regulating tumor cell apoptosis. Furthermore, there are few studies on the impact of the microenvironment on reaction to immune-checkpoint inhibitors (ICIs) in patients with LUAD. Based on the TCGA-LUAD dataset, which is stratified into a training set as well as a validation set in a ratio of 2 : 1, this investigation constructs and validates a prognostic predictive power of a gene signature model of oxidative stress-related prognostic signatures. To ascertain the differences between the high-risk score group and the low-risk score group in tumor-infiltrating lymphocytes and patients’ response to ICI therapy. This oxidative stress-related prognostic gene signature is composed of MAP3K19 and NTSR1 and is an independent prognosis-related factor in the LUAD group. The outcome of patients having a low risk score is better, and the difference was statistically significant, and individuals with a low risk score had a larger number of infiltrating immune cell distribution in the tumor microenvironment, which was closely related to clinical outcome. Our study suggests that the synergistic effect of oxidative stress-related prognostic gene markers-MAP3K19 and NTSR1 has clinical significance in the prognosis identification and immunotherapy of LUAD patients. Thus, the results may help to better intersect the oxidative stress-related mechanisms in clinical value in LUAD but requires prospective validation.
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Yan Lu,William Lemon,Peng-Yuan Liu,Yijun Yi,Carl Morrison,Ping Yang,Zhifu Sun,Janos Szoke,William L Gerald,Mark Watson,Ramaswamy Govindan,Ming You

DOI: https://doi.org/10.1371/journal.pmed.0030467

2006-01-01

PLoS Medicine

Abstract:Background Lung cancer is the leading cause of cancer-related death in the United States. Nearly 50% of patients with stages I and II non-small cell lung cancer (NSCLC) will die from recurrent disease despite surgical resection. No reliable clinical or molecular predictors are currently available for identifying those at high risk for developing recurrent disease. As a consequence, it is not possible to select those high-risk patients for more aggressive therapies and assign less aggressive treatments to patients at low risk for recurrence. Methods and Findings In this study, we applied a meta-analysis of datasets from seven different microarray studies on NSCLC for differentially expressed genes related to survival time (under 2 y and over 5 y). A consensus set of 4,905 genes from these studies was selected, and systematic bias adjustment in the datasets was performed by distance-weighted discrimination (DWD). We identified a gene expression signature consisting of 64 genes that is highly predictive of which stage I lung cancer patients may benefit from more aggressive therapy. Kaplan-Meier analysis of the overall survival of stage I NSCLC patients with the 64-gene expression signature demonstrated that the high-and low-risk groups are significantly different in their overall survival. Of the 64 genes, 11 are related to cancer metastasis (APC, CDH8, IL8RB, LY6D, PCDHGA12, DSP, NID, ENPP2, CCR2, CASP8, and CASP10) and eight are involved in apoptosis (CASP8, CASP10, PIK3R1, BCL2, SON, INHA, PSEN1, and BIK). Conclusions Our results indicate that gene expression signatures from several datasets can be reconciled. The resulting signature is useful in predicting survival of stage I NSCLC and might be useful in informing treatment decisions.
Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

Terry L. Ng,Yiwei Liu,Anastasios Dimou,Tejas Patil,Dara L. Aisner,Zhengwei Dong,Tao Jiang,Chunxia Su,Chunyan Wu,Shengxiang Ren,Caicun Zhou,D. Ross Camidge

DOI: https://doi.org/10.1002/cncr.31871

IF: 6.9209

2018-12-11

Cancer

Abstract:BACKGROUND: This multicenter, retrospective study explored the value of oncogene driver subtype, programmed death-1 ligand (PD-L1) status, and smoking status for predicting which patients with oncogene-driven non-small cell lung cancer (NSCLC) would benefit from treatment with programmed death-1 (PD-1)/PD-L1 inhibitors.METHODS: The clinical features, PD-L1 tumor proportion scores, and PD-1/PD-L1 inhibitor (PDi) outcomes (objective response rate and progression-free survival) of patients who had advanced NSCLC with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations or common, actionable oncogenic drivers were captured.RESULTS: In total, 189 oncogene-positive patients were analyzed. Of these, 104 received a PDi, and 108 had undergone prior PD-L1 testing. The frequency of PD-L1 positivity (≥1%) was higher in patients who had KRAS mutations (P = .031), smokers (P = .006), and non-Asian patients (P = .002). Multivariable analysis indicated that smoking status (P < .001) was the only factor associated significantly with KRAS mutation. The objective response rate to PDi treatment was 16.9% (11 of 65 patients) among smokers (17.3% in the KRAS-mutant and 15.4% in the non-KRAS-mutant smoker subgroups), which was significantly higher than the 0% rate (0 of 26 patients; P = .019) among never-smokers. In subgroup analyses, progression-free survival was influenced by KRAS mutation status (median, 4.57 vs 1.63 months; P = .004), smoking status (4.07 vs 1.73 months; P = .004), PD-L1 positivity (3.8 vs 1.2 months; P = .040), and non-Asian race (3.0 vs 1.97 months; P = .046). In multivariable analysis, only smoking status (P = .008) remained a significant predictor when a PD-L1 level ≥1% was used. However, both smoking status (P = .001) and PD-L1 status (P = .028) were independent predictors when a PD-L1 level ≥50% was used.CONCLUSIONS: Among associated clinical features among patients who have NSCLC with oncogenic drivers, smoking status potentially was the most important, easily available predictor of single PDi efficacy.

oncology
A SWI/SNF-dependent transcriptional regulation mediated by POU2AF2/C11orf53 at enhancer

Aileen Szczepanski,Natsumi Tsuboyama,Huijue Lyu,Ping Wang,Oguzhan Beytullahoglu,Te Zhang,Benjamin David Singer,Feng Yue,Zibo Zhao,Lu Wang

DOI: https://doi.org/10.1038/s41467-024-46492-5

IF: 16.6

2024-03-07

Nature Communications

Abstract:Abstract Recent studies have identified a previously uncharacterized protein C11orf53 (now named POU2AF2/OCA-T1), which functions as a robust co-activator of POU2F3, the master transcription factor which is critical for both normal and neoplastic tuft cell identity and viability. Here, we demonstrate that POU2AF2 dictates opposing transcriptional regulation at distal enhance elements. Loss of POU2AF2 leads to an inhibition of active enhancer nearby genes, such as tuft cell identity genes, and a derepression of Polycomb-dependent poised enhancer nearby genes, which are critical for cell viability and differentiation. Mechanistically, depletion of POU2AF2 results in a global redistribution of the chromatin occupancy of the SWI/SNF complex, leading to a significant 3D genome structure change and a subsequent transcriptional reprogramming. Our genome-wide CRISPR screen further demonstrates that POU2AF2 depletion or SWI/SNF inhibition leads to a PTEN-dependent cell growth defect, highlighting a potential role of POU2AF2-SWI/SNF axis in small cell lung cancer (SCLC) pathogenesis. Additionally, pharmacological inhibition of SWI/SNF phenocopies POU2AF2 depletion in terms of gene expression alteration and cell viability decrease in SCLC-P subtype cells. Therefore, impeding POU2AF2-mediated transcriptional regulation represents a potential therapeutic approach for human SCLC therapy.

multidisciplinary sciences
Identification of POU4F1 as a novel prognostic biomarker and therapeutic target in esophageal squamous cell carcinoma

Nan Li,Siying Chen,Xiao Wang,Boqing Zhang,Boning Zeng,Chao Sun,Kai Zheng,Qiuling Chen,Shaoxiang Wang

DOI: https://doi.org/10.1186/s12935-024-03471-6

2024-08-09

Abstract:Background: Esophageal cancer is a significant global health concern, ranking seventh in incidence and sixth in mortality. It encompasses two pathological types: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma, with ESCC being more prevalent globally and associated with higher mortality rates. The POU (Pit-Oct-Unc) domain family transcription factors, comprising 15 members, play important roles in embryonic development and organ formation. Aberrant expression of POUs has been observed in several human cancers, influencing cell proliferation, tumor invasion, and drug resistance. However, their specific role in ESCC remains unknown. Methods: We analyzed TCGA and GEO databases to assess POUs expression in ESCC tissues. Kaplan-Meier and ROC analyses were used to evaluate the prognostic value of POUs. Gene Set Enrichment Analysis and Protein-Protein interaction network were used to explore the potential pathway. Functional assays (Cell Counting Kit-8, EdU Staining assay, and cloning formation assay) and mechanism analyses (RNA-seq, flow cytometry, and Western blot) were conducted to determine the effects of POU4F1 knockdown on ESCC cell phenotypes and signaling pathways. Results: POU4F1 and POU6F2 were upregulated in various cancer tissues, including ESCC, compared to normal tissues. POU4F1 expression was significantly correlated with patient survival and superior to previous models (AUC = 0.776). Knockdown of POU4F1 inhibited ESCC cell proliferation and affected cell cycle, autophagy, and DNA damage pathways in ESCC cells. Conclusion: POU4F1 is a novel and promising prognostic and therapeutic target for ESCC patients, providing insights into potential treatment strategies.
Smoking As a Predictor of Cell Surface Receptor Anti PD-1/PD-L1, MUC1, and CTLA-4 As the First Line or Monotherapy and Multiple Therapy among Them in NSCLC Patients

Lishi Wang,FengXia Liu,Jing Li,Li Ma,Helin Feng,Qingyi Liu,William Cho,Hai-yong Chen,Hong Chen,Hua Guo,Scott C. Howard,Minghui Li,Baoen Shan,Weikuan Gu,Jia-Fu Ji

DOI: https://doi.org/10.2139/ssrn.3782440

2021-01-01

Abstract:Background: Smokers have been reported to benefit more than non-smokers when treated with programmed death-1 (PD-1) and programmed death-ligand 1 (PD-1/PD-L1) inhibitors in monotherapy or combined with chemotherapy. Methods: This study is a prospectively planned systematic review and meta-analysis of Hazard ratios (HR) of both progression-free survival (PFS) and overall survival (OS) from the randomized clinical trials treated with cancer drugs in different smoking status. Findings: Among all NSCLC patients, when the data from anti- PD-1/PD-L1, anti-CTLA-4, and anti-MUC1 drugs are combined, the mean HR values of smokers and non-smokers were 0·751 and 1.016, respectively. Meta-analysis with a fixed (FE) effect model indicated that the smokers have an HR value of 0·023 lower than that of the non-smokers. Stratified subgroup meta-analysis indicated that when treated with anti-CTLA-4 drugs, smokers had reduced HR values of 0·152 and 0·165 of reduction on average and FE model meta-analysis, respectively. When treated with an anti-MUC1 drug, smokers had reduced HR values of 1·563 and 0·645 of reduction, on average and FE model meta-analysis, respectively. When treated with a combination between nivolumab and ipilimumab drugs, smokers had reduced HR values of 0·257 and 0·141 of reduction, on average and FE model meta-analysis, respectively. Interpretation: Smoking is an easily available clinical response predictor for anti PD/PD-L1 monotherapy or first-line treatment in lung, urothelial carcinoma, and head and neck cancer. Smokers have a higher chance to benefit from MUC1, and CTLA-4 monotherapy in NSCLC. Smoking potentially is a clinical predictor in the treatment of the combination of these three drugs at least in NSCLC patients.Registration: The protocol has been registered at the International Prospective Register of Systematic Reviews (PROSPERO) with the registration number: CRD42019146402.Funding Statement: This work was partially supported by funding from merit grant I01 BX000671 to WG from the Department of Veterans Affairs and the Veterans Administration Medical Center in Memphis, TN, USA and University of Tennessee Health Science Center, TN, USA. The funding sources have no role in any part of the study as well as the manuscript.Declaration of Interests: Authors have no interest of conflict.Ethics Approval Statement: Ethical approval was not required for this study since it involved no patients.
Accumulation of plasmacytoid dendritic cell is associated with a treatment response to DNA-damaging treatment and favorable prognosis in lung adenocarcinoma

Yoon Jin Cha,Eun Young Kim,Yong Jun Choi,Chi Young Kim,Min Kyung Park,Yoon Soo Chang

DOI: https://doi.org/10.3389/fimmu.2023.1154881

2023-06-26

Abstract:Introduction: Favorable responses to the treatment including immune checkpoint inhibitors (ICIs) have been consistently reported in lung cancer with smoking history. As the tumor microenvironment (TME) may be involved in the treatment response to ICIs, we aimed to investigate the TME of lung cancer with different smoking status. Methods: Lung adenocarcinoma (LUAD) tissue (Tu) and adjacent normal-appearing lung tissue (NL) from current and never smokers were investigated by single-cell RNA sequencing and immunofluorescence and immunohistochemical staining. The clinical implications of identified biomarkers were validated using open-source datasets. Results: The lungs of smokers had an increased proportion of innate immune cells in NL tissues, whereas Tu tissues had a lower proportion of these cells than those of non-smokers. Monocyte-derived macrophages (mono-Mc), CD163-LGMN macrophages, monocyte-derived dendritic cells (DCs), and plasmacytoid DCs (pDCs) were significantly enriched in smokers' Tu. Among these clusters, pDCs, specifically enriched in the Tu of smokers. The expression of representative pDC markers, leukocyte immunoglobulin-like receptor A4 (LILRA4) and Toll-like receptor 9 (TLR9), was increased in the stromal cells of LUAD in patients with a smoking history. In an animal model of lung cancer, ionizing radiation induced robust TLR9 expressing immune cells in peritumoral area. Survival analysis using a TCGA-LUAD dataset indicated that patients overexpressing pDC markers exhibited superior clinical outcomes to age-, sex-, and smoking-matched control groups. Top 25% patients with high TLR9 expression exhibited significantly higher tumor mutational burden than that of low TLR9 expression group (bottom 25% patients) (5.81 mutations/Mb vs 4.36 mutations/Mb; P = 0.0059, Welch's two-sample t-test). Conclusion: There is an increased pDC in the TME of smokers' lung cancer, and the response of pDC to DNA damaging treatment would lead a conducive environment to ICIs containing regimens. These findings suggest that R&D that induces an increase in the activated pDC population is continuously required to enhance therapeutic effectiveness of ICIs-containing therapies in lung cancer.
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Jan Norum,Carsten Nieder

DOI: https://doi.org/10.1136/esmoopen-2018-000406

IF: 6.883

2018-01-01

ESMO Open

Abstract:BACKGROUND: Programmed death ligand 1 (PD-L1) targeting immunotherapies, as pembrolizumab and nivolumab, have significantly improved outcome in patients with non-small cell lung cancer (NSCLC). Tobacco smoking is the number one risk factor for lung cancer and is linked to 80%-90% of these cancers. Smoking during cancer therapy may influence on radiotherapy and chemotherapy outcome. We aimed to review the knowledge in immunotherapy.PATIENTS AND METHODS: A systematic review was done. We searched for documents and articles published in English language and registered in Cochrane Library, National Health Service (NHS) Centre for Reviews and Dissemination (CRD), Embase or Medline. The search terms were (A) (Lung cancer or NSCLC) with (pembrolizumab or nivolumab) with PD-L1 with (tobacco or smoking) and (B) Lung Neoplasms and Immunotherapy and (smoking cessation or patient compliance). 68 papers were detected and two more were added during review process (references) and six based on information from the manufacturers.RESULTS: Nine papers were selected. High PD-L1 expression (≥50%) was correlated with current/ever smoking history in three studies. Six studies revealed a higher overall response rate (ORR) among current/former smokers. The ORR was generally (six studies) better among the current/former smoker group. So also when tumours had a molecular 'smoking signature' (one study). This was probably due to a higher mutational burden. In two studies, minor or no difference was revealed.One study (KEYNOTE-024) compared former and current smokers, and documented pembrolizumab being more effective among former smokers than current smokers.CONCLUSIONS: Tobacco smoking patients with NSCLC generally have a higher PD-L1 tumour proportion score and experience a better ORR of immunotherapy than no smokers. There is little evidence on the effect of smoking during immunotherapy, but one study (KEYNOTE-024) may indicate survival gains of smoking cessation.

oncology
Abstract 1980: Cigarette smoke induced oxidative phosphorylation and mitochondrial biogenesis enhance response to immune therapy in NSCLC patients

Yuezhu Wang,Jimmy Ruiz,Yin Liu,Margaret Smith,Gregory Kucera,Umit Topaloglu,Michael Chan,Stacey O’Neill,Jing Su,Fei Xing

DOI: https://doi.org/10.1158/1538-7445.am2022-1980

IF: 11.2

2022-06-17

Cancer Research

Abstract:Background: The treatment regimen of non-small cell lung cancer (NSCLC) has drastically changed owing to the superior anti-cancer effects generated by the immune-checkpoint blockade (ICB). However, only a subset of patients experience benefit after receiving ICBs. There are several treatments including combination of PD-1 blockade and low dose chemotherapy, but only few robust synergetic effects were reported. Therefore, it is of paramount importance to increase the response rate by elucidating the underlying molecular mechanisms and identifying novel therapeutic targets to enhance the efficacy of IBCs in non-responders. Methods: We analyzed the progression-free survival (PFS) and overall survival (OS) of 295 NSCLC patients who received anti-PD-1 therapy by segregating them with multiple clinical factors including sex, age, race, smoking history, BMI, tumor grade and subtype. Tumor samples from 48 patients were sequenced and their genomic profiles were extracted for analyses. We identified key signaling pathways and mutations that are enriched in those patients with distinct responses to ICB by gene set enrichment analysis (GSEA) and mutational analyses. The efficacy of combination treatment with mitochondrial activator, all-trans retinoic acid (ATRA) and PD-1 antibody is evaluated in LL/2 and CMT167 murine lung cancer model. Results: We found that smoking status was the only parameter that was correlated with the ICB responses compared to sex, age, race, BMI, tumor grade and subtype. Former and current smokers have a higher response rate to anti-PD-1 treatment than non-smokers. GSEA results revealed that oxidative phosphorylation (OXPHOS) and mitochondrial related pathways are significantly enriched in both responders and smokers, suggesting a potential role of cellular metabolism in regulating immune response to ICB. We also demonstrated that ATRA which increased mitochondrial function significantly by MitoSox and MitoTrack enhanced the efficacy of anti-PD-1 treatment in vivo. Our clinical and bioinformatics based analyses revealed a connection between smoking induced metabolic switch and the response to immunotherapy, which can be the basis for developing novel combination therapies that are beneficial to never smoked NSCLC patients. Conclusion: In this study, we discovered that smokers respond better to immune therapy than non-smokers due to elevated OXPHOS capacity and mitochondrial activity, which could be a potential target to boost the response to immune therapy in NSCLC patients who never smoked. Citation Format: Yuezhu Wang, Jimmy Ruiz, Yin Liu, Margaret Smith, Gregory Kucera, Umit Topaloglu, Michael Chan, Stacey O'Neill, Jing Su, Fei Xing. Cigarette smoke induced oxidative phosphorylation and mitochondrial biogenesis enhance response to immune therapy in NSCLC patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1980.

oncology
Abstract 6602: Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies

Lanbo Xiao,Tongchen He,Olaf Klingbeil,Young Eleanor,Xiaoli Wu,Yuanyuan Qiao,Abhijit Parolia,Sanjana Eyunni,Rahul Mannan,Somnath Mahapatra,NamHoon Kim,Heng Zheng,Fengyun Su,Xuhong Cao,Susanta Samajdar,Murali Ramachandra,Christopher R. Vakoc,Arul M. Chinnaiyan

DOI: https://doi.org/10.1158/1538-7445.am2024-6602

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Background: Small cell lung cancer (SCLC) is a rapidly progressing subtype of lung cancer with a high growth rate and early metastasis propensity, often resulting in a more advanced disease stage at diagnosis. A recent transcriptome analysis of human SCLC tumors revealed that SCLC could be characterized by the expression pattern of certain transcription factors (TFs), including ASCL1 (achaete-scute family bHLH transcription factor 1) and POU2F3 (POU domain class 2 transcription factor 3), exemplifying SCLC as a TF-driven malignancy. ASCL1-driven SCLC (SCLC-A) manifests a neuroendocrine phenotype, while POU2F3-driven SCLC (SCLC-P) is characterized as a tuft-cell-like variant. Recent studies revealed that POU domain class 2 transcription factors uniquely rely on coactivators to achieve their lineage-defining functions in the tuft cell and B cell lineages. In tuft-cell-like SCLC cells, the coactivators of POU2F3 (POU2AF2 and POU2AF3) endow POU2F3 with a critical transactivation domain by forming a master regulator complex, which supports enhancer-mediated cancer-promoting gene activation in SCLC-P cells. This indicates a potential therapeutic vulnerability of tuft-cell-like SCLC whereby strategies aimed at blocking POU2F3-POU2AF2/3 function may lead to clinical benefit. Methods: We conducted a domain-targeted CRISPR screen to identify druggable targets for SCLC-P, followed by pharmacological validation in preclinical SCLC models. Multi-omics techniques, including ATAC-seq, ChIP-seq, RNA-seq, and RIME, were employed to elucidate the SWI/SNF complex's regulatory influence on the POU2F-POU2AF axis. Results: Here we identified that the POU2F3 molecular subtype of SCLC (SCLC-P) exhibits an exquisite dependence on the activity of the SWI/SNF epigenetic complex. SCLC-P cell lines were sensitive to low nanomolar levels of a SWI/SNF ATPase degrader when compared to other molecular subtypes of SCLC. Co-factors of POU2F were found to interact with components of the SWI/SNF complex. The POU2F3 transcription factor complex is evicted from chromatin upon SWI/SNF ATPase degradation. A novel, orally bioavailable SWI/SNF ATPase PROTAC degrader demonstrated preferential efficacy in SCLC-P relative to the SCLC-A subtype. The SWI/SNF ATPase PROTAC degrader did not alter normal tuft cell numbers in lung or colon, nor did it exhibit toxicity in mice. B cell malignancies which displayed a dependency on the POU2F co-factor, POU2AF1, were also remarkably sensitive to SWI/SNF ATPase degradation. In a POU2AF1-dependent, disseminated murine model of multiple myeloma, AU-24118 had an enhanced survival benefit as compared to pomalidomide, an approved treatment for multiple myeloma. Conclusions: Taken together, our studies suggest that POU2F-POU2AF driven malignancies have an intrinsic dependence on the SWI/SNF complex representing a striking therapeutic vulnerability. Citation Format: Lanbo Xiao, Tongchen He, Olaf Klingbeil, Young Eleanor, Xiaoli Wu, Yuanyuan Qiao, Abhijit Parolia, Sanjana Eyunni, Rahul Mannan, Somnath Mahapatra, NamHoon Kim, Heng Zheng, Fengyun Su, Xuhong Cao, Susanta Samajdar, Murali Ramachandra, Christopher R. Vakoc, Arul M. Chinnaiyan. Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6602.

oncology
Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients.

Deyao Xie,Linhua Lan,Kate Huang,Lin Chen,Cuicui Xu,Rongrong Wang,Yang Shi,Xiaoyi Wu,Lu Wang,Yongzhang Liu,Bin Lu

DOI: https://doi.org/10.3892/or.2014.3538

2014-01-01

Oncology Reports

Abstract:Non-small cell lung cancer (NSCLC) accounts for approximately 80-85% of all lung cancer cases. Cigarette smoking is the number one risk factor which is attributed to more than four out of five cases of lung cancers. The prognostic impact of cell cycle regulation-associated tumor suppressors including p53 and p21 for NSCLC is still controversial. In the present study, we examined p53 and p21 expression using immunoblotting in tumor and adjacent non-cancerous tissues from NSCLC patients. Moreover, tissue microarrays (TMAs) including 150 specimens was used to examine p53 and p21 expression by immunohistochemical staining (IHC). The association between p53/p21 and various clinicopathological characteristics was evaluated. Kaplan-Meier overall survival was used to analyze the association between p53/p21 expression and prognosis of NSCLC patients, as well as the association of cigarette smoking with p53/p21 expression and prognosis. The results of the immunoblotting showed that expression of p53 and p21 in tumor tissues was significantly higher than that in the matched adjacent non-cancerous tissues (P<0.001 and P<0.05, respectively). The IHC results showed that 50.67% of the cases had high expression of p21; however, the percentage of patients having high expression of p53 was 31.3%. Univariate and Cox regression models were used to evaluate the factors related to prognosis with p53 and p21 expression. Multivariate analysis indicated that p53 expression was an independent prognostic factor for NSCLC (P=0.005), while p21 could not serve as an independent prognostic factor (P=0.123). In addition, smoking history was closely related to lung cancer risk (P=0.041), but could not be an independent assessment factor (P=0.740). In this study, we further demonstrated the association of p53/p21 expression and cigarette smoking. Our results suggest that cigarette smoking and overexpression of p53 or p21 are associated with poor prognosis. The combination of p53/p21 expression and smoking history may be a useful biomarker for tumor progression and prognosis of NSCLC patients.
Identification of Prognostic Biomarkers of Smoking-Related Lung Cancer.

Chen Liang,Wei Pan,Zhijun Zhou,Xiaomin Liu

DOI: https://doi.org/10.21037/jtd-23-1890

2024-01-01

Journal of Thoracic Disease

Abstract:Background:The early diagnosis and effective prognostic treatment measures for lung cancer are still limited, leading to a 5-year survival rate of less than 15% for these patients. Smoking is one of the causes of lung cancer, but it is not the initial carcinogenic factor. It is not clear what specific mechanism cigarette induces lung cancer, and there is a lack of research on the relationship between related genes and the prognosis of patients with smoking lung cancer. The objective of this study was to provide new theoretical evidence and potential therapeutic targets for the mechanisms of smoking-related lung cancer formation.Methods:The gene expression profile data from the GSE12428 dataset which includes 63 lung cancer and normal tissue pairs were downloaded from the Gene Expression Omnibus (GEO) database, and data from smokers with lung cancer [both lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)] from The Cancer Genome Atlas (TCGA) database were analyzed. The differential genes in smokers with lung cancer were screened using the linear model for microarray data via R software. The differential gene enrichment analysis was performed using the online analysis software Database for Annotation, Visualization and Integrated Discovery (DAVID). The expression levels of differential genes and their correlation with patient tumor clinical stage were analyzed using gene expression profiling interactive analysis (GEPIA). The overall survival rate was analyzed using Kaplan-Meier curves.Results:In the GSE12428 dataset, 225 upregulated genes and 565 downregulated genes were identified in cancer tissues; based on smoking status, 1 upregulated gene and 4 downregulated genes were identified. Among smokers who also had lung cancer, 4 genes were downregulated, namely CSH1, BPIFA1, SLPI, and SCGB3A1. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis revealed that these genes were mainly associated with biological functions such as antibacterial response, humoral immune response, and response to external stimuli. Among them, BPIFA1, SLPI, and SCGB3A1 expression was decreased in lung cancer tissues, with SCGB3A1 showing significant differences. Additionally, high expression of SCGB3A1 was associated with favorable prognosis in patients with lung cancer.Conclusions:Three genes BPIFA1, SLPI and SCGB3A1, were identified as being associated with smokers with lung cancer, with SCGB3A1 showing a close correlation with patient prognosis. These findings provide potential new targets for the treatment of lung cancer. Certainly, this study needs to more investigate the mechanism of these genes regulation.
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival

Maria Teresa Landi,Tatiana Dracheva,Melissa Rotunno,Jonine D Figueroa,Huaitian Liu,Abhijit Dasgupta,Felecia E Mann,Junya Fukuoka,Megan Hames,Andrew W Bergen,Sharon E Murphy,Ping Yang,Angela C Pesatori,Dario Consonni,Pier Alberto Bertazzi,Sholom Wacholder,Joanna H Shih,Neil E Caporaso,Jin Jen

DOI: https://doi.org/10.1371/journal.pone.0001651

IF: 3.7

2008-02-20

PLoS ONE

Abstract:Background: Tobacco smoking is responsible for over 90% of lung cancer cases, and yet the precise molecular alterations induced by smoking in lung that develop into cancer and impact survival have remained obscure. Methodology/principal findings: We performed gene expression analysis using HG-U133A Affymetrix chips on 135 fresh frozen tissue samples of adenocarcinoma and paired noninvolved lung tissue from current, former and never smokers, with biochemically validated smoking information. ANOVA analysis adjusted for potential confounders, multiple testing procedure, Gene Set Enrichment Analysis, and GO-functional classification were conducted for gene selection. Results were confirmed in independent adenocarcinoma and non-tumor tissues from two studies. We identified a gene expression signature characteristic of smoking that includes cell cycle genes, particularly those involved in the mitotic spindle formation (e.g., NEK2, TTK, PRC1). Expression of these genes strongly differentiated both smokers from non-smokers in lung tumors and early stage tumor tissue from non-tumor tissue (p<0.001 and fold-change >1.5, for each comparison), consistent with an important role for this pathway in lung carcinogenesis induced by smoking. These changes persisted many years after smoking cessation. NEK2 (p<0.001) and TTK (p = 0.002) expression in the noninvolved lung tissue was also associated with a 3-fold increased risk of mortality from lung adenocarcinoma in smokers. Conclusions/significance: Our work provides insight into the smoking-related mechanisms of lung neoplasia, and shows that the very mitotic genes known to be involved in cancer development are induced by smoking and affect survival. These genes are candidate targets for chemoprevention and treatment of lung cancer in smokers.
The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

Yueqin Sun,Qi Yang,Jie Shen,Ting Wei,Weitao Shen,Nan Zhang,Peng Luo,Jian Zhang

DOI: https://doi.org/10.3389/fcell.2021.745859

IF: 5.5

2021-09-28

Frontiers in Cell and Developmental Biology

Abstract:Background: The emergence of immune checkpoint inhibitors (ICIs) has opened a new chapter for the treatment of non-small cell lung cancer (NSCLC), and the best beneficiaries of ICI treatment are still being explored. Smoking status has been repeatedly confirmed to affect the efficacy of ICIs in NSCLC patients, but the specific mechanism is still unclear. Methods: We performed analysis on the Memorial Sloan Kettering Cancer Center (MSKCC) clinical NSCLC cohort receiving ICI treatment, The Cancer Genome Atlas (TCGA) Pan-Lung Cancer cohort, and Gene Expression Omnibus (GEO) database GSE41271 lung cancer cohort that did not receive ICI treatment, including survival prognosis, gene mutation, copy number variation, immunogenicity, and immune microenvironment, and explored the impact of smoking status on the prognosis of NSCLC patients treated with ICIs and possible mechanism. In addition, 8 fresh NSCLC surgical tissue samples were collected for mass cytometry (CyTOF) experiments to further characterize the immune characteristics and verify the mechanism. Result: Through the analysis of the clinical data of the NSCLC cohort treated with ICIs in MSKCC, it was found that the smokers in NSCLC receiving ICI treatment had a longer progression-free survival (HR: 0.69, 95% CI: 0.49–0.97, p = 0.031) than those who never smoked. Further analysis of the TCGA and GEO validation cohorts found that the differences in prognosis between different groups may be related to the smoking group’s higher immunogenicity, higher gene mutations, and stronger immune microenvironment. The results of the CyTOF experiment further found that the immune microenvironment of smoking group was characterized by higher expression of immune positive regulatory chemokine, and higher abundance of immune activated cells, including follicular helper CD4 + T cells, gamma delta CD4 + T cells, activated DC, and activated CD8 + T cells. In contrast, the immune microenvironment of non-smoking group was significantly enriched for immunosuppressive related cells, including regulatory T cells and M2 macrophages. Finally, we also found highly enriched CD45RA high CD4 + T cells and CD45RA high CD8 + T cells in the non-smoking group. Conclusion: Our research results suggest that among NSCLC patients receiving ICI treatment, the stronger immunogenicity and activated immune microenvironment of the smoking group make their prognosis better.

cell biology,developmental biology
Abstract 3934: Smoking's influence on divergent paths to lung cancer

Edward James Evans,Fabio Marongiu,Emilia Lim,Oriol Pich,Yonghua Zhuang,Dexiang Gao,William Hill,Cian Murphy,Ryan Turner,Moumita Ghosh,York Miller,Mariam Jamal-Hanjani,Charles Swanton,James DeGregori

DOI: https://doi.org/10.1158/1538-7445.am2024-3934

IF: 11.2

2024-03-28

Cancer Research

Abstract:Lung cancer is the leading cause of cancer mortality in the world. Many studies have highlighted how mutagens from cigarette smoke promote specific mutations such as G12 mutations in KRAS, contributing to clonal evolution that leads to lung cancer. Despite the indisputable correlation between smoking and lung cancer, people who have never smoked account for the 7th leading cause of cancer mortality. Given the differences in predominant exposures, we hypothesize that the clonal evolution between people with and without smoking histories are markedly different. Therefore, we analyzed lung samples from people with different cigarette smoking exposure to elucidate smoking's effect on the somatic mutational landscape in the progression to lung cancer. To observe somatic mutations subjected to different exposures of smoking, we used a rare-mutation detection technique called DuplexSeq to analyze somatic variants from 200+ lung samples. We acquired DNA from cells from bronchoscopy brushings and lung punches of histologically normal tissue from people with and without lung cancer and who currently, formerly, or never smoked cigarettes. Through collaborations, we characterized mutations using bioinformatic pipelines, various databases, and statistical methods. In samples from people who smoke, we observe an enhancement of mutations with higher variant allele frequencies and pervasive positive selection acting on mutations in many cancer-associated genes. From our bronchoscopy brushings, NOTCH1 mutations show the most definitive increase of protein-altering variants, while NF1 and KRAS show a predominance of driver mutation in lung punches. Unexpectedly, people without lung cancer who never smoked had a notable presence of pathogenic mutations in PTEN and PIK3CA. Furthermore, multiple punches from the same individual highlight how expansions of mutations have stronger similarity within an individual than across individuals regardless of smoking status. This association points to the importance of the inherent lung microenvironment in influencing the mutational landscapes in lung cancer progression. Altogether, these results show how smoking increases the oncogenicity of observable mutations in the lung but does not preclude the presence of oncogenic clones, emphasizing the value of precision diagnoses and prevention. Ongoing research will be centered around functional assays to determine the impact of observed mutations on tissue function and longitudinal studies using mutational landscapes as a proxy for lung cancer risk. Citation Format: Edward James Evans, Fabio Marongiu, Emilia Lim, Oriol Pich, Yonghua Zhuang, Dexiang Gao, William Hill, Cian Murphy, Ryan Turner, Moumita Ghosh, York Miller, Mariam Jamal-Hanjani, Charles Swanton, James DeGregori. Smoking's influence on divergent paths to lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3934.

oncology
Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy

Chia-Hsin Liu,Zhong Chen,Kong Chen,Fu-Tien Liao,Chia-En Chung,Xiaoping Liu,Yu-Chun Lin,Phouthone Keohavong,George D Leikauf,Yuanpu Peter Di,George D. Leikauf

DOI: https://doi.org/10.1158/0008-5472.can-20-1994

IF: 11.2

2020-10-29

Cancer Research

Abstract:Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that is associated with increased risk of lung cancer. <i>Pseudomonas aeruginosa</i> (PA) infections are frequent in patients with COPD, which increase lung inflammation and acute exacerbations. However, the influences of PA-induced inflammation on lung tumorigenesis and the efficacy of immune checkpoint blockade remain unknown. In this study, we initiated a murine model of lung cancer by treating FVB/NJ female mice with tobacco carcinogen nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) alone or in combination with PA-lipopolysaccharide (LPS). LPS-mediated chronic inflammation induced T-cell exhaustion, increased the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis, and enhanced NNK-induced lung tumorigenesis through an immunosuppressive microenvironment characterized by accumulation of myeloid-derived suppressive cells (MDSC) and regulatory T cells. Anti-PD-1 antibody treatment reduced tumors in NNK/LPS-treated mice with a 10-week LPS treatment but failed to inhibit tumor growth when LPS exposure was prolonged to 16 weeks. Anti-Ly6G antibody treatment coupled with depletion of MDSC alone reduced tumor growth; when combined with anti-PD-1 antibody, this treatment further enhanced antitumor activity in 16-week NNK/LPS-treated mice. Immune gene signatures from a human lung cancer dataset of PD-1 blockade were identified, which predicted treatment responses and survival outcome and overlapped with those from the mouse model. This study demonstrated that LPS-mediated chronic inflammation creates a favorable immunosuppressive microenvironment for tumor progression and correlates with the efficacy of anti-PD-1 treatment in mice. Immune gene signatures overlap with human and mouse lung tumors, providing potentially predictive markers for patients undergoing immunotherapy. SIGNIFICANCE: This study identifies an immune gene signature that predicts treatment responses and survival in patients with tobacco carcinogen-induced lung cancer receiving immune checkpoint blockade therapy.

oncology
Author Correction: the Aryl Hydrocarbon Receptor Mediates Tobacco-Induced PD-L1 Expression and is Associated with Response to Immunotherapy.

Gui-Zhen Wang,Li Zhang,Xin-Chun Zhao,San-Hui Gao,Li-Wei Qu,Hong Yu,Wen-Feng Fang,Yong-Chun Zhou,Fan Liang,Chen Zhang,Yun-Chao Huang,Zhihua Liu,Yang-Xin Fu,Guang-Biao Zhou

DOI: https://doi.org/10.1038/s41467-022-30871-x

IF: 16.6

2019-01-01

Nature Communications

Abstract:Whether tobacco carcinogens enable exposed cells immune escape resulting in carcinogenesis, and why patients who smoke respond better to immunotherapies than non-smokers, remains poorly understood. Here we report that cigarette smoke and the carcinogen benzo(a)pyrene (BaP) induce PD-L1 expression on lung epithelial cells in vitro and in vivo, which is mediated by aryl hydrocarbon receptor (AhR). Anti-PD-L1 antibody or deficiency in AhR significantly suppresses BaP-induced lung cancer. In 37 patients treated with anti-PD-1 antibody pembrolizumab, 13/16 (81.3%) patients who achieve partial response or stable disease express high levels of AhR, whereas 12/16 (75%) patients with progression disease exhibit low levels of AhR in tumor tissues. AhR inhibitors exert significant antitumor activity and synergize with anti-PD-L1 antibody in lung cancer mouse models. These results demonstrate that tobacco smoke enables lung epithelial cells to escape from adaptive immunity to promote tumorigenesis, and AhR predicts the response to immunotherapy and represents an attractive therapeutic target.
Abstract 1748: Dearth of smoking-induced mutations in oncogene-driven NSCLCs despite smoking exposure

Chen-Yang Huang,Nanhai Jiang,Meixin Shen,Gillianne Lai,Aaron C. Tan,Amit Jain,Stephanie P. Saw,Mei-Kim Ang,Quan Sing Ng,Darren Wan-Teck Lim,Ravindran Kanesvaran,Eng-Huat Tan,Wan Ling Tan,Boon-Hean Ong,Kevin L. Chua,Devanand Anantham,Angela Takano,Tony KH Lim,Wai Leong Tam,Ngak Leng Sim,Anders J. Skanderup,Daniel S.W. Tan,Steven G. Rozen

DOI: https://doi.org/10.1158/1538-7445.am2024-1748

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Non-small cell lung cancers (NSCLCs) in non-smokers are mostly driven by mutations in the oncogenes EGFR, ERBB2, and MET, and fusions involving ALK and RET. We term these “non-smoking-related oncogenes” (NSROs). NSRO-driven tumors account for approximately half of NSCLCs in East Asia, and, alarmingly, their age-adjusted incidence is increasing for unknown reasons. In addition to occurring in non-smokers, NSRO-driven tumors also occur in smokers. However, the clonal architecture and genomic landscape of these tumors remain largely unexplored. Here, we investigated genomic and transcriptomic alterations in 173 tumor sectors from 48 patients with NSRO-driven or typical-smoking NSCLCs. Overall, NSRO-driven NSCLCs in smokers and non-smokers had similar genomic landscapes and clonal architectures that were distinct from those in typical-smoking NSCLCs. Surprisingly, even in patients with prominent smoking histories, the mutational signature caused by tobacco smoking was essentially absent in NSRO-driven NSCLCs. We confirmed this unexpected finding in two large NSCLC data sets from other geographic regions. However, we observed differences in the tumor transcriptomes of NSRO-driven NSCLCs in smokers and non-smokers, with tumors in smokers displaying higher transcriptomic activities related to regulation of the cell cycle. This suggested that smoking does have an impact on tumor phenotype in NSCRO-driven NSCLC, likely through non-genetic mechanisms. We concluded that NSRO-driven NSCLCs, whether in non-smokers or smokers, constitute an important disease entity that is very different from typical-smoking NSCLC. Citation Format: Chen-Yang Huang, Nanhai Jiang, Meixin Shen, Gillianne Lai, Aaron C. Tan, Amit Jain, Stephanie P. Saw, Mei-Kim Ang, Quan Sing Ng, Darren Wan-Teck Lim, Ravindran Kanesvaran, Eng-Huat Tan, Wan Ling Tan, Boon-Hean Ong, Kevin L. Chua, Devanand Anantham, Angela Takano, Tony KH Lim, Wai Leong Tam, Ngak Leng Sim, Anders J. Skanderup, Daniel S.W. Tan, Steven G. Rozen. Dearth of smoking-induced mutations in oncogene-driven NSCLCs despite smoking exposure [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1748.

oncology
Abstract 4467: Plasmacytoid dendritic cells, prevalent in the TME of smokers, is associated with a good prognosis and treatment response of LUAD

Eun Young Kim,Yoon Jin Cha,Yong Jun Choi,Min Kyung Park,Yoon Soo Chang

DOI: https://doi.org/10.1158/1538-7445.am2023-4467

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Background: Attempts to find therapeutic biomarkers through investigation of subgroup showing good responses to certain drugs in cancer often yielded meaningful results. Smoker’s lung adenocarcinoma has consistently shown a favorable response to immune checkpoint inhibitors (ICIs) than non-smoker’s lung adenocarcinoma. Comparing the macrophages (Mφ) and dendritic cells (DC) constituting the innate immune tumor microenvironment (TME) in lung cancer of smokers and nonsmokers, we tried to figure out the difference in TME and biomarkers that predict the therapeutic response to ICIs. Methods: The inflammatory TME of current and never smokers’ lung cancer was explored by tumor and adjacent normal appearing lung tissues (Tu and NL hereafter) scRNA sequencing and verified by IF, IHC, and open-source dataset. Results: Compared to lungs of nonsmokers, smokers’ lung have an increased proportion of cell populations involved in innate immunity, and the increased cell population was mostly Mφ, which were enriched in NL. When the number of Mφ present in the NL of the corresponding individual were taken as the denominator, Tu of smokers has a lower proportion of Mφ than that of non-smokers. Further sub-clustering of Mφ and DCs showed that FCN1-mono and CD163-LGMN Mφ, which correspond to the initial differentiation into the resident cell population within the tissue, and mo-DC, cDC2, and pDC were significantly enriched in the Tu. Among them, pDC is a functionally differentiated tissue resident cell that showed a different tissue distribution pattern between smokers and non-smokers, so it was estimated as one of the causes of the different treatment response to ICIs between the two patient groups. The difference of pDC’s distribution was further verified through IHC staining using anti-LILRA4 and anti-TLR9 antibody, showing pDC was significantly enriched in the smokers’ TME. A significant increase in TLR9 expression was observed in or around lung cancer immediately after ionizing radiation or cisplatin treatment in LSL-Kras G12D mouse model. The survival analysis of TCGA-LUAD dataset showed that the patients' overexpressing pDC markers such as IRF4 and TLR9 was superior clinical outcomes to the age, gender and smoking matched control group. Comparing the difference in TMB between the top 25% and bottom 25% groups according to the expression of TLR9, it was 5.81/Mb in the upper group and 4.36/Mb in the subgroup, showing a significant difference. Conclusions: pDC is an innate immune cell population that showed a prominent increase in smokers’ TME compared to that of non-smokers, suggesting that its increase may be one the factors that smokers’ lung cancer show favorable responses to ICI than that of non-smokers. These findings suggest that the pDC signature can be developed as a biomarker predicting the response to ICIs and increasing the number of pDCs or its activity may improve treatment outcome of ICIs. Citation Format: Eun Young Kim, Yoon Jin Cha, Yong Jun Choi, Min Kyung Park, Yoon Soo Chang. Plasmacytoid dendritic cells, prevalent in the TME of smokers, is associated with a good prognosis and treatment response of LUAD. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4467.

oncology
SIPA1L3 Methylation Modifies the Benefit of Smoking Cessation on Lung Adenocarcinoma Survival: an Epigenomic–smoking Interaction Analysis

Ruyang Zhang,Linjing Lai,Xuesi Dong,Jieyu He,Dongfang You,Chao Chen,Lijuan Lin,Ying Zhu,Hui Huang,Sipeng Shen,Liangmin Wei,Xin Chen,Yichen Guo,Liya Liu,Li Su,Andrea Shafer,Sebastian Moran,Thomas Fleischer,Maria Moksnes Bjaanaes,Anna Karlsson,Maria Planck,Johan Staaf,Aslaug Helland,Manel Esteller,Yongyue Wei,Feng Chen,David C. Christiani

DOI: https://doi.org/10.1002/1878-0261.12482

2019-01-01

Molecular Oncology

Abstract:Smoking cessation prolongs survival and decreases mortality of patients with non‐small‐cell lung cancer (NSCLC). In addition, epigenetic alterations of some genes are associated with survival. However, potential interactions between smoking cessation and epigenetics have not been assessed. Here, we conducted an epigenome‐wide interaction analysis between DNA methylation and smoking cessation on NSCLC survival. We used a two‐stage study design to identify DNA methylation–smoking cessation interactions that affect overall survival for early‐stage NSCLC. The discovery phase contained NSCLC patients from Harvard, Spain, Norway, and Sweden. A histology‐stratified Cox proportional hazards model adjusted for age, sex, clinical stage, and study center was used to test DNA methylation–smoking cessation interaction terms. Interactions with false discovery rate‐q ≤ 0.05 were further confirmed in a validation phase using The Cancer Genome Atlas database. Histology‐specific interactions were identified by stratification analysis in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. We identified one CpG probe (cg02268510SIPA1L3) that significantly and exclusively modified the effect of smoking cessation on survival in LUAD patients [hazard ratio (HR)interaction = 1.12; 95% confidence interval (CI): 1.07–1.16; P = 4.30 × 10–7]. Further, the effect of smoking cessation on early‐stage LUAD survival varied across patients with different methylation levels of cg02268510SIPA1L3. Smoking cessation only benefited LUAD patients with low methylation (HR = 0.53; 95% CI: 0.34–0.82; P = 4.61 × 10–3) rather than medium or high methylation (HR = 1.21; 95% CI: 0.86–1.70; P = 0.266) of cg02268510SIPA1L3. Moreover, there was an antagonistic interaction between elevated methylation of cg02268510SIPA1L3 and smoking cessation (HRinteraction = 2.1835; 95% CI: 1.27–3.74; P = 4.46 × 10−3). In summary, smoking cessation benefited survival of LUAD patients with low methylation at cg02268510SIPA1L3. The results have implications for not only smoking cessation after diagnosis, but also possible methylation‐specific drug targeting.

Lymphocyte and plasma cell neoplasms associated with autoimmune diseases.

A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

A SWI/SNF-dependent transcriptional regulation mediated by POU2AF2/C11orf53 at enhancer

Identification of POU4F1 as a novel prognostic biomarker and therapeutic target in esophageal squamous cell carcinoma

Smoking As a Predictor of Cell Surface Receptor Anti PD-1/PD-L1, MUC1, and CTLA-4 As the First Line or Monotherapy and Multiple Therapy among Them in NSCLC Patients

Accumulation of plasmacytoid dendritic cell is associated with a treatment response to DNA-damaging treatment and favorable prognosis in lung adenocarcinoma

Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature

Abstract 1980: Cigarette smoke induced oxidative phosphorylation and mitochondrial biogenesis enhance response to immune therapy in NSCLC patients

Abstract 6602: Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies

Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients.

Identification of Prognostic Biomarkers of Smoking-Related Lung Cancer.

Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival

The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

Abstract 3934: Smoking's influence on divergent paths to lung cancer

Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy

Author Correction: the Aryl Hydrocarbon Receptor Mediates Tobacco-Induced PD-L1 Expression and is Associated with Response to Immunotherapy.

Abstract 1748: Dearth of smoking-induced mutations in oncogene-driven NSCLCs despite smoking exposure

Abstract 4467: Plasmacytoid dendritic cells, prevalent in the TME of smokers, is associated with a good prognosis and treatment response of LUAD

SIPA1L3 Methylation Modifies the Benefit of Smoking Cessation on Lung Adenocarcinoma Survival: an Epigenomic–smoking Interaction Analysis